Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18207901 | 0.84 | SLC6A2 (0.33) | — | |
| SCHEMBL12361216 | 0.83 | MEN1 (0.33) | — | |
| SCHEMBL7853102 | 0.80 | EPAS1 (0.32) | — | |
| SCHEMBL7108202 | 0.78 | EPAS1 (0.32) | — | |
| SCHEMBL7844498 | 0.78 | EPAS1 (0.32) | — | |
| SCHEMBL8036894 | 0.78 | EPAS1 (0.32) | — | |
| SCHEMBL5682444 | 0.78 | L3MBTL1 (0.38) | GRIN1GRIN2A | |
| SCHEMBL16877425 | 0.77 | SLC6A2 (0.38) | — | |
| SCHEMBL7855663 | 0.76 | — | — | |
| SCHEMBL22589204 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3962909-B1 | NOVEL OXALYL PIPERAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO KG (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-20220202814-A1 | TREATMENT OF CANCER | MINGSIGHT PHARMACEUTICALS, INC. | 2022-06-30 | — | — | US | disclosed |
| US-20210163455-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2020221811-A1 | NOVEL OXALYL PIPERAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2020-11-05 | — | — | WO | disclosed |
| EP-3670509-A1 | INHIBITORS OF INV(16) LEUKEMIA | The University of Virginia Patent Foundation (US) | 2020-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163455-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GRIN1 803/4885GRIN2A 1113/4885 |
| US-20220202814-A1 | TREATMENT OF CANCER | PRKACB, PRKDC, PRKCH | GRIN1 4291/4885GRIN2A 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.